Cargando…
Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond
SIMPLE SUMMARY: The treatment of patients with relapsed/refractory multiple myeloma has advanced considerably in recent years, irrespective of whether they are younger or older patients. Treating patients with relapsed/refractory multiple myeloma and renal impairment is far more complicated than tre...
Autores principales: | Bozic, Boris, Rutner, Jens, Zheng, Chang, Ruckser, Reinhard, Selimi, Flonza, Racz, Krysztina, Köcher, Martin, Tatzreiter, Georg, Sebesta, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533858/ https://www.ncbi.nlm.nih.gov/pubmed/34680184 http://dx.doi.org/10.3390/cancers13205036 |
Ejemplares similares
-
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018) -
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C. S., et al.
Publicado: (2019) -
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
por: Podar, Klaus, et al.
Publicado: (2021) -
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021) -
Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)